NETRIS Pharma is pleased to announce that a "trial in progress" abstract has been accepted to the ESMO congress (European Society for Medical Oncology) taking place September 16th-20th. The corresponding...
Read More
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA® December 31, 2020 LYON, France – NETRIS Pharma, a…
NETRIS Pharma will attend the Bio Partnering @ JPM conference that will take place Virtual (Jan 11th-15th, 2021). Our team members will be pleased to meet with you and discuss…
December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m…
NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…
NETRIS Pharma is pleased to announce the arrival of Frédéric Le Bras, MD; as the new company Chief Medical Officer. Graduated from René Descartes University in Paris, Frédéric obtained his...
Read More
NETRIS Pharma will attend the 2019 Bio-Europe conference in Hamburg, Germany (November 11th-13th). Our team members will be pleased to meet with you and discuss Business Development and investment opportunities. Please...
Read More
Dr Philippe Cassier, Principal Investigator of NETRIS Pharma Phase 1 dose-escalation clinical trial on solid tumors, will present the results of the trial at ESMO Conference in Barcelona. The presentation...
Read More
NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…
NETRIS Pharma will attend the Colloque on Women Cancer in Paris (March 30th, 2019). In partnership with “La Ligue contre le Cancer” Association, the following theme will be discussed by…
NETRIS Pharma will attend the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 07th-10th, 2019). Our team members attending the event will be pleased to meet you for…
NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to have…
NETRIS Pharma will attend the 2018 BIO International Convention event in Boston, MA (June 04th-07th). Our team members attending the event will be pleased to meet you for discussing opportunities…
NETRIS Pharma will attend PEGS 2018 event in Boston, MA (April 30th-May 04th). Our CEO, Pr. Patrick Mehlen, will give a presentation on April 30th within the Oncology stream – Antibodies…
NETRIS Pharma will attend the BIO-Europe Spring 2018 event in Amsterdam, Netherlands (March 12th-14th). Our team members attending the event will be pleased to meet you for discussing opportunities with…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…
NETRIS Pharma will attend the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 08th-11th, 2018). Our team members attending the event will be pleased to meet you…
Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence…